Oncology Weekly

08/22/2024

G6PD inhibition leads to oxidative stress and cell death in tumors, boosting the efficacy of immunotherapies.- https://buff.ly/3yA5eN8

08/19/2024

Patients with low G6PD expression have better outcomes with ICIs, suggesting a new therapeutic strategy.- https://buff.ly/3yA5eN8

08/16/2024

SRS/FSR for CSM yields high CNN recovery rates and long-term tumor control, with SRS showing quicker improvements. -

KEY TAKEAWAYS The study aimed to evaluate CNNs recovery in patients with CSM and assess the effectiveness of treatment. The results revealed that...

08/14/2024

ML classifiers' accuracy in predicting PCR in breast cancer evaluated. - https://buff.ly/4bWDWhL

08/13/2024

Study shows low G6PD expression in tumors improves immune response and outcomes of immune checkpoint inhibitors. -

KEY TAKEAWAYS The study aimed to investigate how low G6PD expression affects tumor immunity and ICI treatment outcomes. G6PD inhibition triggers...

08/12/2024

Upfront resection in elderly glioblastoma patients significantly improves survival rates.

KEY TAKEAWAYS The study aimed to determine if resection improves survival over biopsy in elderly patients with glioblastoma through a meta-analysis. ...

08/12/2024

Study: SRS/FSR for CSM shows significant CNNs recovery and excellent long-term radiological control. - https://buff.ly/3WMsbWG

08/08/2024

Upfront resection improves survival in elderly glioblastoma patients, study reveals.

KEY TAKEAWAYS The study aimed to determine if resection improves survival over biopsy in elderly patients with glioblastoma through a meta-analysis. ...

08/07/2024

Study shows COX-2 overexpression is linked to worse prognosis in breast cancer, correlated with TNM staging and histological grading. -

KEY TAKEAWAYS The study aimed to evaluate COX-2 overexpression as a prognostic marker in BC through comparison with histopathological parameters and TNM...

08/06/2024

G6PD inhibition triggers immunogenic cell death, enhancing immunotherapy effectiveness against tumors. -

KEY TAKEAWAYS The study aimed to investigate how low G6PD expression affects tumor immunity and ICI treatment outcomes. G6PD inhibition triggers...

08/06/2024

FDA reviews Immorta Bio's Senovax IND application for NSCLC. Potential breakthrough in lung cancer treatment on the horizon. -

FDA has granted an Investigational New Drug (IND) application to Immorta Bio Inc. to initiate a clinical trial evaluating # the safety, immunogenicity, and...

08/05/2024

Study compares ML classifiers for predicting PCR in breast cancer. -

KEY TAKEAWAYS The study aimed to compare the performance of ML classifiers in predicting pCR in BC using radiomics from pre- and post-contrast T1WI. ...

08/05/2024

SRS/FSR treatments for CSM lead to effective cranial nerve recovery and sustained tumor control. -

KEY TAKEAWAYS The study aimed to evaluate CNNs recovery in patients with CSM and assess the effectiveness of treatment. The results revealed that...

08/02/2024

Can ML improve PCR prediction in BC? Dive into the latest comparison of classifiers and find out! -

KEY TAKEAWAYS The study aimed to compare the performance of ML classifiers in predicting pCR in BC using radiomics from pre- and post-contrast T1WI. ...

07/31/2024

ICI + Antiangio-Ab leads in safety for NSCLC post-ICI failure -

KEY TAKEAWAYS The study aimed to investigate the optimal systemic treatment options for patients with NSCLC following the failure of ICIs. ...

07/30/2024

Study highlights potential of ARS model in LUAD treatment and prognosis. https://buff.ly/3W8nGpm

07/29/2024

Improved survival in elderly glioblastoma patients through upfront resection.

KEY TAKEAWAYS The study aimed to determine if resection improves survival over biopsy in elderly patients with glioblastoma through a meta-analysis. ...

07/28/2024

Study: TKI + Chemo superior for PFS, ORR; ICI + TKI for OS in NSCLC post-ICI failure. -

KEY TAKEAWAYS The study aimed to investigate the optimal systemic treatment options for patients with NSCLC following the failure of ICIs. ...